Advertisement for orthosearch.org.uk
Results 1 - 20 of 25
Results per page:
Bone & Joint Research
Vol. 12, Issue 10 | Pages 654 - 656
16 Oct 2023
Makaram NS Simpson AHRW

Cite this article: Bone Joint Res 2023;12(10):654–656.


Bone & Joint Research
Vol. 12, Issue 1 | Pages 5 - 8
1 Jan 2023
Im G

Cite this article: Bone Joint Res 2023;12(1):5–8.


The Bone & Joint Journal
Vol. 106-B, Issue 7 | Pages 640 - 641
1 Jul 2024
Ashby E Haddad FS


Bone & Joint Research
Vol. 12, Issue 5 | Pages 306 - 308
1 May 2023
Sharrock M Board T

Cite this article: Bone Joint Res 2023;12(5):306–308.


Bone & Joint Research
Vol. 13, Issue 12 | Pages 790 - 792
17 Dec 2024
Mangwani J Brockett C Pegg E

Cite this article: Bone Joint Res 2024;13(12):790–792.


Bone & Joint Research
Vol. 11, Issue 8 | Pages 514 - 517
10 Aug 2022
Little CB Zaki S Blaker CL Clarke EC

Cite this article: Bone Joint Res 2022;11(8):514–517.


The Bone & Joint Journal
Vol. 104-B, Issue 5 | Pages 529 - 531
1 May 2022
Rajput V Haddad FS


Bone & Joint Research
Vol. 11, Issue 5 | Pages 301 - 303
17 May 2022
Clement ND Skinner JA Haddad FS Simpson AHRW


Bone & Joint Research
Vol. 11, Issue 1 | Pages 29 - 31
20 Jan 2022
Ma M Tan Z Li W Zhang H Liu Y Yue C


Bone & Joint Research
Vol. 11, Issue 1 | Pages 26 - 28
20 Jan 2022
Ma M Tan Z Li W Zhang H Liu Y Yue C


Bone & Joint Research
Vol. 10, Issue 12 | Pages 840 - 843
15 Dec 2021
Al-Hourani K Tsang SJ Simpson AHRW


Bone & Joint Research
Vol. 10, Issue 5 | Pages 307 - 309
3 May 2021
Eitner A Wildemann B


Bone & Joint Research
Vol. 10, Issue 2 | Pages 134 - 136
1 Feb 2021
Im G

The high prevalence of osteoarthritis (OA), as well as the current lack of disease-modifying drugs for OA, has provided a rationale for regenerative medicine as a possible treatment modality for OA treatment. In this editorial, the current status of regenerative medicine in OA including stem cells, exosomes, and genes is summarized along with the author’s perspectives. Despite a tremendous interest, so far there is very little evidence proving the efficacy of this modality for clinical application. As symptomatic relief is not sufficient to justify the high cost associated with regenerative medicine, definitive structural improvement that would last for years or decades and obviate or delay the need for joint arthroplasty is essential for regenerative medicine to retain a place among OA treatment methods.

Cite this article: Bone Joint Res 2021;10(2):134–136.


Bone & Joint 360
Vol. 9, Issue 5 | Pages 3 - 3
1 Oct 2020
Ollivere B


The Bone & Joint Journal
Vol. 101-B, Issue 8 | Pages 889 - 890
1 Aug 2019
Haddad FS Masri BA


Bone & Joint Research
Vol. 8, Issue 6 | Pages 224 - 225
1 Jun 2019
Wilkinson JM


Bone & Joint Research
Vol. 7, Issue 12 | Pages 636 - 638
1 Dec 2018
Roussot MA Haddad FS


Bone & Joint Research
Vol. 7, Issue 3 | Pages 223 - 225
1 Mar 2018
Jones LD Golan D Hanna SA Ramachandran M


Bone & Joint Research
Vol. 6, Issue 10 | Pages 610 - 611
1 Oct 2017
Simpson AHRW


The Bone & Joint Journal
Vol. 99-B, Issue 6 | Pages 705 - 707
1 Jun 2017
Witt JD Haddad FS